Arctic Bioscience AS (OSL:ABS)

Market Cap	91.32M
Revenue (ttm)	45.90M
Net Income (ttm)	-43.36M
Shares Out	26.86M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,248
Average Volume	32,114
Open	3.500
Previous Close	3.400
Day's Range	3.100 - 3.690
52-Week Range	1.650 - 14.900
Beta	1.32
RSI	50.75
Earnings Date	Nov 28, 2025

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Oslo Børs
• Ticker Symbol: ABS

Financial Performance

In 2024, Arctic Bioscience AS's revenue was 44.40 million, an increase of 31.55% compared to the previous year's 33.76 million. Losses were -47.93 million, 5.31% more than in 2023.